the questions, answered from the record
CJC-1295: frequently asked questions
Direct answers drawn from the published literature — definitional, pharmacokinetic and safety — with the honest gaps left in plain view.
Definitions
What is CJC-1295?
A synthetic long-acting analog of growth-hormone-releasing hormone, built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds a covalent serum-albumin link for a multi-day half-life [1][2]. It is a single research peptide, not a blend.
What does CJC-1295 do?
It binds the GHRH receptor on pituitary somatotrophs and stimulates synthesis and release of growth hormone, which raises hepatic IGF-1 [2][3]. In humans, single doses elevated GH and IGF-1 for days [2].
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide GHRH analog that stimulates the body's own growth-hormone release via the GHRH receptor [2]. It is not an anabolic-androgenic steroid and does not act on androgen receptors.
What is CJC-1295 DAC?
CJC-1295 carrying the albumin-binding DAC moiety, giving it a multi-day duration of action [1]. It is distinct from no-DAC "Modified GRF 1-29," which keeps the four substitutions but is short-acting [1].
What is CJC-1295 with DAC?
The variant whose C-terminal lysine carries a maleimidopropionyl linker that covalently bonds to circulating serum albumin — the Drug Affinity Complex — extending the plasma half-life toward that of albumin itself [1].
Safety and side effects
CJC-1295 side effects and safety signals in the literature
CJC-1295 has no large or long-term safety trials in healthy adults [9]. The documented and theoretical concerns trace to sustained stimulation of the GH/IGF-1 axis: fluid retention and edema from GH-driven sodium reabsorption, effects on insulin sensitivity, injection-site reactions, immunogenicity, and the epidemiologic association between higher IGF-1 and modestly increased risk of certain cancers [9][14]. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295 [9].
Is CJC-1295 safe?
CJC-1295 is an unapproved research chemical with no large or long-term safety trials in healthy adults [9]. Reported and theoretical concerns include fluid retention, effects on insulin sensitivity, immunogenicity, and the epidemiologic link between higher IGF-1 and some cancers [9][14].
Are CJC-1295 peptides safe?
There is no controlled long-term safety evidence in healthy adults [9]. The literature notes fluid-retention and insulin-sensitivity effects of GH-axis stimulation, immunogenicity concerns, and IGF-1/cancer epidemiology as reasons for caution [9][14].
What are the side effects of CJC-1295?
Concerns documented for GH-axis stimulation include fluid retention and edema, effects on insulin sensitivity, injection-site reactions, immunogenicity, and the theoretical IGF-1/cancer-risk question [9][14]. Controlled human safety data are limited.
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis [2][3]. There is no robust human evidence that it raises or lowers testosterone; studies have focused on GH and IGF-1 endpoints [2].
Does CJC-1295 lower testosterone?
No human evidence shows CJC-1295 lowers testosterone; it works through the GHRH/GH/IGF-1 axis rather than the reproductive axis [2][3].
Regulatory status
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved for human use anywhere and is handled as a research chemical [9]. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other concerns and did not recommend it for the 503A compounding bulks list [9]. It is also prohibited at all times in sport under WADA Section S2 [9].
Effects and expectations
What to expect when taking CJC-1295?
In research subjects, CJC-1295 produced dose-dependent multi-day elevations of GH and IGF-1 while preserving the natural pulsatile pattern of GH secretion [2][3]. Outcomes in non-trial use are not characterized, and no controlled efficacy trial in healthy adults has measured downstream results [9].